GNTA Stock Overview
A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genenta Science S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.02 |
| 52 Week High | US$7.28 |
| 52 Week Low | US$2.20 |
| Beta | 0.74 |
| 11 Month Change | -8.73% |
| 3 Month Change | 22.44% |
| 1 Year Change | -7.89% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.36% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Genenta Science's (NASDAQ:GNTA) Cash Burn Rate
Jan 26
We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Jul 21We're Not Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn
Dec 10We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Sep 09Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach
Jul 25Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
Mar 18Shareholder Returns
| GNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | -10.3% | -2.1% |
| 1Y | -7.9% | 13.6% | 29.6% |
Return vs Industry: GNTA underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: GNTA underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| GNTA volatility | |
|---|---|
| GNTA Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GNTA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Pierluigi Paracchi | www.genenta.com |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
Genenta Science S.p.A. Fundamentals Summary
| GNTA fundamental statistics | |
|---|---|
| Market cap | US$91.82m |
| Earnings (TTM) | -US$9.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.8x
P/E RatioIs GNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNTA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €8.92m |
| Earnings | -€8.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GNTA perform over the long term?
See historical performance and comparison